RxDoctor Payments Data

Jordan Roussel, MD

Gastroenterology · Biloxi, MSNPI 1205290350

Payments from drug & device makers

$4,891in general payments, 2019–2025

Across 248 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$376
  • Takeda Pharmaceuticals U.S.A., Inc.$353
  • Gilead$336
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$261
  • Bristol Myers Squibb$201
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$4,891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,891 in reported general payments places this provider in the 50th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$140,254
Medicare patients
624
Services billed
1,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide15$683,723
EpclusaSofosbuvir/Velpatasvir27$647,197
LinzessLinaclotide32$31,103
ViberziEluxadoline11$14,303
Colestipol Hcl111$11,100
Ursodiol13$3,209
Omeprazole261$2,129
Dexlansoprazole DrDexlansoprazole11$1,762
Dicyclomine Hcl33$742
Pantoprazole Sodium52$648
Esomeprazole Magnesium23$334
Baclofen11$283
Ondansetron Hcl16$186
Ondansetron OdtOndansetron12$166
Metronidazole13$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$353$683,72315 claims
GileadEpclusa$336$647,19727 claims
AbbVieLinzess, Viberzi$1,922$45,40643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →